Full-Time
Cancer-specific electronic health record platform
No salary listed
Junior, Mid
Durham, NC, USA
Hybrid role with 3 office days set by you and your team.
Flatiron Health improves cancer care and research with its cancer-specific Electronic Health Record (EHR) system, which helps healthcare providers manage patient information and enhances the patient experience. The platform integrates real-world data in real-time, facilitating collaboration among community oncologists, academic researchers, and life sciences companies to accelerate cancer research and improve care quality. Unlike competitors, Flatiron offers its EHR on a subscription basis and provides access to valuable data for developing new cancer treatments. The company's goal is to transform oncology through high-quality data and patient care.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
$2.2B
Headquarters
New York City, New York
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Work/life autonomy via flexible work hours and flexible paid time off
Generous parental leave (16 weeks for either parent)
Transition back to work program following parental leave
Child and caregiver travel benefits for new parents
Backup child care
Weekly meditation sessions
Flatiron-sponsored fitness classes
Weekly massages and manicures available onsite (employee funded)
What You Should Know: – Flatiron Health, a healthtech company focused on revolutionizing clinical research through technology integration, has announced a collaboration with NRG Oncology, a clinical research consortium within the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN). – The partnership aims to deploy Flatiron’s Clinical Pipe™ in a multicenter NRG clinical trial, streamlining data entry and accelerating study timelines.Supporting NCI-Sponsored Trials w/ NRG OncologyFlatiron Clinical Pipe™, a cutting-edge electronic health record (EHR) to electronic data capture (EDC) connector, is designed to significantly improve the efficiency and reduce the time and effort required for clinical study data entry. By automating the transfer of data from EHRs to EDC systems, the technology minimizes manual data entry, a known burden for clinical trial site teams.This collaboration marks a significant expansion of Flatiron Clinical Pipe™ use cases, now extending to NCTN-sponsored studies. By leveraging Flatiron’s EHR-to-EDC technology, NRG Oncology seeks to alleviate the administrative burden on its network of over 1,300 research sites worldwide, streamline data management, and accelerate the pace of clinical trials.In conjunction with the trial deployment, NRG and Flatiron will conduct a correlative study to rigorously assess the efficiency of Flatiron Clinical Pipe™ compared to traditional data entry methods. This study will provide valuable insights into the real-world impact of the technology on clinical trial workflows.Flatiron Clinical Pipe Research/OutcomesPrevious research published in the journal ESMO Real World Data and Digital Oncology has demonstrated the significant time-saving potential of Flatiron Clinical Pipe™. The study revealed that teams using the technology were able to accurately transfer thousands of data points, representing the completion of hundreds of case report forms (CRFs), with an average completion time of just 37 seconds per CRF. This represents a substantial reduction in data entry time over the course of a clinical trial.“We are very excited about the rich potential of this collaboration with our partners at Flatiron, a leader in healthcare systems technology
Reduce Clinical Trial Burden with Flatiron Clinical Pipe™: EHR-to-EDC Integration. by Fred Pennic 03/05/2025 Leave a Comment. What You Should Know: – Flatiron Health, a healthcare technology company, today announced a collaboration with the University of Colorado Comprehensive Cancer Center (CU Cancer Center) and UCHealth to implement Flatiron Clinical Pipe™, an innovative solution that streamlines data capture for clinical trials. – The partnership aims to accelerate cancer research and improve patient care by reducing administrative burden and enhancing the efficiency of clinical studies.Flatiron Clinical Pipe™Flatiron Clinical Pipe™ is an electronic health record (EHR) to electronic data capture (EDC) connector that automates the transfer of clinical trial data from the EHR to the EDC system. This eliminates the need for manual data entry, which is often time-consuming and prone to errors.Key features and benefits of Flatiron Clinical Pipe include: Reduced administrative burden: Eliminates manual data entry, freeing up research staff to focus on other critical tasks.Improved accuracy: Reduces errors associated with manual data entry, ensuring data integrity and reliability.Enhanced efficiency: Accelerates the clinical trial process by streamlining data capture and analysis.Increased capacity: Enables research sites to conduct more clinical trials and enroll more patients.Improved patient care: Allows clinicians to spend more time with patients and less time on administrative tasks.Real-World ImpactResearch published in ESMO Real-World Data and Digital Oncology demonstrates the significant impact of Flatiron Clinical Pipe. Users were able to transfer data in an average of 37 seconds, significantly faster than manual entry methods. The platform enabled the efficient transfer of thousands of data points, streamlining the clinical trial process.“Collaborating with the CU Cancer Center and UCHealth, market-leading and innovative cancer care providers, is an incredible opportunity to advance our shared vision to reimagine how clinical trials are executed,” said Emily Akin, Head of Research Network at Flatiron Health
Ambry Genetics, operator of a genetics diagnostics company intended to provide a comprehensive suite of genetic testing applications for inherited and non-inherited diseases, was acquired by Tempus AI for $600 million.
What You Should Know:– Flatiron Health, a leading technology company focused on improving cancer care announced a strategic partnership with Exact Sciences, a pioneer in cancer screening and diagnostics to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease (MRD) test, Oncodetect™.– The collaboration will leverage Flatiron’s innovative clinical research platform and extensive network of community oncology practices to study the test’s performance in diverse patient populations and real-world settings.Leverage Real-World Data and Community Oncology Settings to Advance Cancer CareMRD testing is a rapidly evolving field in oncology, with the potential to transform cancer care by detecting residual disease after treatment and guiding personalized treatment decisions. However, generating robust clinical evidence for MRD tests can be challenging and time-consuming.This partnership aims to address this challenge by:Leveraging real-world data: Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting.Utilizing data from Flatiron’s network of community oncology practices to generate evidence in a real-world setting. Focusing on diverse patient populations: Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials.Ensuring that the study includes a broad range of patients, including those typically underrepresented in clinical trials. Accelerating evidence generation: Employing a novel prospective clinical evidence generation platform and pragmatic study design to expedite the research process.First Patient EnrolledThe partnership has already achieved a significant milestone with the enrollment of the first patient in the study in under six months from conception. This rapid progress highlights the strong collaboration and commitment to execution between Flatiron Health and Exact Sciences.“Our partnership with Exact Sciences leverages Flatiron’s next-generation prospective evidence platform, which we designed to address critical evidence gaps via studies embedded into routine care, with unprecedented speed,” said Alex Deyle, general manager, Clinical Research, Flatiron Health. “Our in-house team of experts, experienced site network, fit-for-purpose research operations, and cutting-edge technology that focuses on reducing site burden, has enabled us to run more efficient and representative prospective studies.”
- Willowglade Technologies(R), provider of the only Unified Digital Patient Experience(TM) Platform available to oncology practices nationwide, announced a new partnership with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology.